Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.

Author(s): Karakousis C, Blumenson L

Affiliation(s): Surgical Oncology Department, Roswell Park Cancer Institute, Buffalo, New York 14263.

Publication date & source: 1993, Eur J Cancer., 29A(13):1831-5.

Publication type: Clinical Trial; Randomized Controlled Trial

173 patients with regional lymphatic metastases (n = 139) or distant disease (n = 34) were prospectively randomised, following resection of all clinically detectable tumour, to observation (n = 88) or adjuvant chemotherapy (n = 85). The treatment group received 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) 80 mg/m2 intravenously (i.v.) every 4 weeks, and actinomycin-D 10 micrograms/kg, vincristine 1.0 mg/m2 i.v. every 2 weeks for 6 months. The disease-free survival curves between the two groups were significantly different (P = 0.03). The estimated 5-year disease-free survival rate for the observation group was 9% and for the treatment group 29%. However, the overall survival curves were not significantly different for the two groups. Nitrosoureas may have a weak effect as adjuvant treatment in malignant melanoma.